A clinical trial is a controlled study to evaluate the safety and efficacy (how well it works) of an experimental drug treatment. These studies are required before a drug can be approved by a regulatory agency such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA). The purpose of a clinical trial is to evaluate whether a potential new therapy is safe and effective. Patients interested in participating in a clinical trial must meet certain eligibility criteria and be willing to follow directions of the physician in charge of the study.
 

Clinical Trials with pepinemab

Recruiting
NCT04381468

SIGNAL-AD Alzheimer’s Disease
Evaluating the Safety and Efficacy of our drug Pepinemab in Patients with Alzheimer’s Disease.
Phase 1b/2

Condition(s) Alzheimer Disease (AD)

SPONSOR

COLLABORATORS
Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation

What is Alzheimer's Disease?

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.

Trial Purpose

Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat.

Trial Details

Phase

Phase 1b/2

Dates

Actual Study Start Date
September 3, 2020

First Patient Enrolled Date
December 31, 2021

Estimated Primary Completion Date
November 2021

Estimated Study Completion Date
December 31, 2021

Sponsor

Vaccinex, Inc.

Collaborators

Alzheimer’s Association
Alzheimer’s Drug Discovery Foundation

Products

pepinemab
placebo

About the Trial

All patients who enroll in the trial will receive pepinemab once each month by intravenous infusion.

Conditions
Ages
Genders

Click for more information about our Neurology Programs

Recruiting
NCT04815720

Keynote B84 Head and Neck Cancer
Evaluating the Safety and Efficacy of our Drug Pepinemab in Combination with Pembrolizumab in Patients with Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Phase 1b/2

Condition(s) Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

SPONSOR

COLLABORATOR

Click for more information about our Cancer Programs